CL2016001609A1 - Composiciones farmacéuticas que comprenden azd9291. - Google Patents

Composiciones farmacéuticas que comprenden azd9291.

Info

Publication number
CL2016001609A1
CL2016001609A1 CL2016001609A CL2016001609A CL2016001609A1 CL 2016001609 A1 CL2016001609 A1 CL 2016001609A1 CL 2016001609 A CL2016001609 A CL 2016001609A CL 2016001609 A CL2016001609 A CL 2016001609A CL 2016001609 A1 CL2016001609 A1 CL 2016001609A1
Authority
CL
Chile
Prior art keywords
azd9291
pharmaceutical compositions
understands
cancer
tablet
Prior art date
Application number
CL2016001609A
Other languages
English (en)
Spanish (es)
Inventor
David Wilson
Cindy Finnie
Steven Anthony Raw
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50191689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001609(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2016001609A1 publication Critical patent/CL2016001609A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2016001609A 2014-01-02 2016-06-22 Composiciones farmacéuticas que comprenden azd9291. CL2016001609A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1400034.3A GB201400034D0 (en) 2014-01-02 2014-01-02 Pharmaceutical Compositions comprising AZD9291

Publications (1)

Publication Number Publication Date
CL2016001609A1 true CL2016001609A1 (es) 2016-12-09

Family

ID=50191689

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001609A CL2016001609A1 (es) 2014-01-02 2016-06-22 Composiciones farmacéuticas que comprenden azd9291.

Country Status (37)

Country Link
US (6) US10183020B2 (enExample)
EP (1) EP3089741B1 (enExample)
JP (1) JP6588915B2 (enExample)
KR (1) KR102336378B1 (enExample)
CN (2) CN114712362A (enExample)
AR (1) AR098989A1 (enExample)
AU (1) AU2015204218B2 (enExample)
CA (1) CA2933403C (enExample)
CL (1) CL2016001609A1 (enExample)
CR (1) CR20160310A (enExample)
CY (1) CY1124848T1 (enExample)
DK (1) DK3089741T3 (enExample)
DO (1) DOP2016000156A (enExample)
EA (1) EA034243B9 (enExample)
ES (1) ES2873226T3 (enExample)
GB (1) GB201400034D0 (enExample)
GT (1) GT201600142A (enExample)
HR (1) HRP20210749T1 (enExample)
HU (1) HUE054344T2 (enExample)
IL (1) IL246186B (enExample)
LT (1) LT3089741T (enExample)
MX (1) MX367358B (enExample)
MY (1) MY183536A (enExample)
NI (1) NI201600098A (enExample)
NZ (1) NZ721298A (enExample)
PE (1) PE20161170A1 (enExample)
PH (1) PH12016501310B1 (enExample)
PL (1) PL3089741T3 (enExample)
PT (1) PT3089741T (enExample)
RS (1) RS61927B1 (enExample)
SG (1) SG11201605339QA (enExample)
SI (1) SI3089741T1 (enExample)
SM (1) SMT202100330T1 (enExample)
TW (1) TWI702953B (enExample)
UY (1) UY35933A (enExample)
WO (1) WO2015101791A1 (enExample)
ZA (1) ZA201605300B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (enExample) 2014-01-24 2018-02-24
US10513509B2 (en) 2016-05-26 2019-12-24 Recurium Ip Holdings, Llc EGFR inhibitor compounds
CN108057036B (zh) * 2016-11-07 2023-06-13 正大天晴药业集团股份有限公司 一种egfr抑制剂的固体药物组合物
CN107176954B (zh) * 2017-06-02 2019-01-11 无锡双良生物科技有限公司 一种egfr抑制剂的药用盐及其晶型、制备方法和应用
CN110013468B (zh) * 2018-01-09 2022-02-18 北京福元医药股份有限公司 一种azd9291氘代衍生物药物制剂
WO2019138346A1 (en) * 2018-01-10 2019-07-18 Alembic Pharmaceuticals Limited Pharmaceutical composition of osimertinib
SG11202007414XA (en) * 2018-02-12 2020-09-29 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
KR102738945B1 (ko) * 2018-03-01 2024-12-04 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를 포함하는 약학 조성물
KR102511672B1 (ko) * 2018-03-23 2023-03-17 우시 상량 바이오테크놀로지 씨오., 엘티디. 의약 조성물, 그 제조방법 및 사용
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
KR20210144844A (ko) 2019-03-29 2021-11-30 아스트라제네카 아베 비-소세포 폐암의 치료에 사용하기 위한 오시머티닙
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
JP2023510426A (ja) 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
TW202304457A (zh) * 2021-03-22 2023-02-01 瑞典商阿斯特捷利康公司 配製物
IL315848A (en) 2022-03-31 2024-11-01 Astrazeneca Ab Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment
EP4514793A1 (en) 2022-04-28 2025-03-05 Astrazeneca AB Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
TW202417040A (zh) 2022-06-27 2024-05-01 瑞典商阿斯特捷利康公司 涉及用於治療癌症的上皮生長因子受體酪胺酸激酶抑制劑之組合
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
CN120584108A (zh) 2023-01-06 2025-09-02 英斯梅德股份有限公司 新型可逆dpp1抑制剂及其用途
WO2025092926A1 (zh) * 2023-10-31 2025-05-08 浙江同源康医药股份有限公司 一种嘧啶类衍生物的药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110376A (en) * 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
WO2001076565A1 (fr) * 2000-04-12 2001-10-18 Banyu Pharmaceutical Co., Ltd. Compositions et preparations se desintegrant dans la cavite buccale
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
MY135609A (en) 2002-02-26 2008-05-30 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
JP2008515786A (ja) * 2004-10-05 2008-05-15 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング プロトンポンプアンタゴニスト用の経口医薬調剤
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
NZ570381A (en) * 2006-02-09 2011-02-25 Daiichi Sankyo Co Ltd Anti-cancer pharmaceutical composition
JP5576922B2 (ja) * 2006-04-20 2014-08-20 信越化学工業株式会社 腸溶性固体分散体を含んでなる固形製剤
WO2009009778A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
EP2696857A1 (en) 2011-04-11 2014-02-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising bosentan
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
ES2791308T3 (es) * 2011-07-27 2020-11-03 Astrazeneca Ab Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer
ES2946549T3 (es) * 2012-01-13 2023-07-20 Xspray Pharma Ab Publ Composición farmacéutica de nilotinib
WO2013160916A1 (en) 2012-04-25 2013-10-31 Hetero Research Foundation Sunitinib malate solid dispersion
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291

Also Published As

Publication number Publication date
PE20161170A1 (es) 2016-11-24
SI3089741T1 (sl) 2021-08-31
DK3089741T3 (da) 2021-06-07
CN114712362A (zh) 2022-07-08
US20250017930A1 (en) 2025-01-16
PH12016501310A1 (en) 2016-09-14
EA034243B1 (ru) 2020-01-21
RS61927B1 (sr) 2021-06-30
IL246186A0 (en) 2016-07-31
CY1124848T1 (el) 2022-11-25
ZA201605300B (en) 2022-10-26
IL246186B (en) 2020-07-30
AU2015204218A1 (en) 2016-07-07
PH12016501310B1 (en) 2022-07-06
CR20160310A (es) 2016-09-23
US20190111057A1 (en) 2019-04-18
TW201609101A (zh) 2016-03-16
MX2016008744A (es) 2016-09-08
LT3089741T (lt) 2021-06-10
SG11201605339QA (en) 2016-07-28
NI201600098A (es) 2016-12-20
CA2933403A1 (en) 2015-07-09
HUE054344T2 (hu) 2021-08-30
JP6588915B2 (ja) 2019-10-09
TWI702953B (zh) 2020-09-01
US20200360378A1 (en) 2020-11-19
EA201691242A1 (ru) 2016-12-30
GT201600142A (es) 2019-08-12
SMT202100330T1 (it) 2021-07-12
MY183536A (en) 2021-02-25
JP2017501201A (ja) 2017-01-12
HK1225655A1 (zh) 2017-09-15
EP3089741B1 (en) 2021-03-10
PL3089741T3 (pl) 2021-09-27
EA034243B9 (ru) 2020-04-10
DOP2016000156A (es) 2016-08-15
KR102336378B1 (ko) 2021-12-08
CA2933403C (en) 2022-03-29
US20160324854A1 (en) 2016-11-10
UY35933A (es) 2015-07-31
CN105848647B (zh) 2022-04-26
ES2873226T3 (es) 2021-11-03
CN105848647A (zh) 2016-08-10
WO2015101791A1 (en) 2015-07-09
AU2015204218B2 (en) 2017-06-15
MX367358B (es) 2019-08-16
EP3089741A1 (en) 2016-11-09
NZ721298A (en) 2017-10-27
PT3089741T (pt) 2021-06-11
GB201400034D0 (en) 2014-02-19
AR098989A1 (es) 2016-06-22
KR20160101720A (ko) 2016-08-25
HRP20210749T1 (hr) 2021-06-25
US20220395502A1 (en) 2022-12-15
US10183020B2 (en) 2019-01-22
US20240189310A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
MX378273B (es) Compuestos activos hacia bromodominios.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
MX2018006240A (es) Composiciones que comprenden cepas bacterianas.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2016001364A1 (es) Moduladores de ror gamma (rory)
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
HUE053449T2 (hu) Kompozíciók, amelyek tartalmazzák lizinspecifikus demetiláz-1 inhibitorát, amelynek van pirimidingyûrûje és azok felhasználása rák kezelésében
CL2016003260A1 (es) Profármacos de gemcitabina
CL2015002897A1 (es) Inhibidores de bace1
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.